←
Bloodman5,411 posts
Bloodman avatar

Bloodman

@Bloodman

Tom DeLoughery - Hematologist at Oregon Health Science University

◷ Joined October 2008▧ 660 Photos and videos
Bloodman avatar
Bloodman@Bloodman·Nov 12

Happy Oregon Exploding Whale Day!

On November 12, 1970, the body of a 45-foot, 8-ton whale, which had washed ashore along the coast of Oregon, was infamously blown up by the Oregon Department of Transportation in an attempt to dispose of the carcass

1:28
JAMA avatar
⟳ Bloodman retweeted
JAMA@JAMA_current·Nov 9

💬 Viewpoint by Hanny Al-Samkari, MD, Scott Olitsky, MD, and Michael Auerbach, MD: The new FDA boxed warning for #FerricCarboxymaltose identifies a significant risk of #Hypophosphatemia and related complications, including osteomalacia, fractures, cardiac arrhythmias, and neuromuscular dysfunction. The warning follows a successful FDA Citizen Petition and adds regulatory attention to adverse effects associated with intravenous iron treatment. ja.ma/4etMmRP

Post attachment
Bloodman avatar
Bloodman@Bloodman·Nov 10

A new anticoagulant!!!

MAJOR The U.S. Food and Drug Administration today approved Sunharbo (#asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a #stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” “Stroke is a leading cause of disability and death in the United States, and survivors are at risk of having another stroke,” said Hylton V. Joffe, M.D., MMSc, Director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology in the FDA’s Center for Drug Evaluation and Research. “Today’s approval represents a meaningful advance for patients and health care providers seeking a new option for secondary stroke prevention.” The effectiveness of Sunharbo was demonstrated in the OCEANIC-STROKE study, a multicenter, randomized, double-blind, placebo-controlled phase 3 study that enrolled 12,327 adults. Participants had a recent non-cardioembolic ischemic stroke (NIH Stroke Scale ≤15) or high-risk TIA and were randomly assigned to Sunharbo or placebo within 72 hours of symptom onset. Both groups also received antiplatelet therapy. Sunharbo 50 mg once daily significantly reduced the risk of ischemic stroke by 26% compared to placebo over a median treatment of 14.2 months. The overall rate of major bleeding was similar between the Sunharbo and placebo groups but was increased with Sunharbo in patients older than 75 years and during the first 90 days of treatment. Gastrointestinal bleeding occurred more commonly with Sunharbo compared to placebo. The most frequently reported adverse reaction (occurring in 3% or greater of Sunharbo-treated patients) was diarrhea. Concomitant use with medicines that are combined P-gp and strong CYP3A4 inducers (such as carbamazepine) is not recommended because these medicines may decrease Sunharbo’s effectiveness. Sunharbo is not recommended in patients with moderate or severe hepatic impairment. Sunharbo should be withheld at least 24 hours before elective surgery or invasive procedures and for at least 24 hours after thrombolysis for acute ischemic stroke. Sunharbo is not approved for stroke prevention in patients with atrial fibrillation. The FDA granted Sunharbo Fast Track and Priority Review designations. The approval was granted to Bayer HealthCare Pharmaceuticals Inc., Whippany, N.J. fda.gov/news-events/press-an…

Bloodman avatar
Bloodman@Bloodman·Nov 2

Excellent thread!!

1/8 🧵 Should we routinely withhold IV iron in hospitalized patients with infections? Many clinicians do, fearing that iron promotes bacterial growth. But does the evidence justify this practice? Our new Things We Do for No Reason™️ article in @JHospMedicine examines this question.

HemOnc Today avatar
⟳ Bloodman retweeted
HemOnc Today@HemOncToday·Oct 30

New #ASH guidelines in @BloodAdvances for #IronDeficiency diagnosis set higher ferritin thresholds for: 👧Children ages 9 months to 4 years 🤰Adults & pregnant/menstruating individuals 🩸Other high-risk groups, such as those with heavy menstrual bleeding vist.ly/5qqtw

Bloodman avatar
Bloodman@Bloodman·Sep 27

More reassuring data on transdermal HRT

Compared with no use of hormone therapy, oral menopausal hormone therapy was associated with increased venous thromboembolic risk regardless of dosage & treatment duration, finds study. No increased thrombotic risks were observed with transdermal therapy bmj.com/content/394/bmj-2026…

Post attachment
Toby Richards avatar
⟳ Bloodman retweeted
Toby Richards@TobyRichardsUEL·Aug 20

Intravenous iron to treat anaemia in surgery The Largest and probably final RCT - (ITACS): IV iron before cardiac surgery improved patient outcomes and reduced transfusion: bmj.com/content/394/bmj-2026…

Ron Barbosa MD FACS avatar
⟳ Bloodman retweeted
Ron Barbosa MD FACS@rbarbosa91·Aug 16

Followup 🧵 to my 🧵from last year on Lord of The Rings-related traumatic injuries: Here we will explore the many injuries of Frodo Baggins, a notorious trauma recidivist and high-intensity user of the Middle-Earth health care system. His outcome was, sadly, unsurprising. 1/

Post attachmentPost attachment
Annals of Int Med avatar
⟳ Bloodman retweeted
Annals of Int Med@AnnalsofIM·Jul 28

Trending now at Annals.org: Iron deficiency anemia (IDA) is the most common cause of anemia worldwide, and women of reproductive age are disproportionately affected due to menstrual blood loss and gynecologic disorders. In an Annals #BeyondTheGuidelines feature, two hematologists and coauthors of the 2025 Iron Consortium Guideline debate the diagnosis, evaluation, and treatment of patients with IDA in the context of a young woman with IDA and heavy menstrual bleeding. bit.ly/3Tg30Nd

Post attachment